Interference RNA as a new tool and possible future therapy for inflammatory lung disease

M. Lindsay (London, United Kingdom)

Source: Lung Science Conference 2005 - Evidence-based medicine for respiratory disease with special emphasis on inflammatory processes

Number: 9

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Lindsay (London, United Kingdom). Interference RNA as a new tool and possible future therapy for inflammatory lung disease. Lung Science Conference 2005 - Evidence-based medicine for respiratory disease with special emphasis on inflammatory processes

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Advances in treatment of complex lung disease: will targeted therapy with anticalins be clinically applied in the near future? Source: International Congress 2019 – Inhaled medicines and biological therapies in the current era of systemic treatments Year: 2019
N-ethyl-N-nitrosourea mutagenesis: a new tool for exploring lung disease Source: Annual Congress 2010 - Scientific Year in Review Year: 2010
Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021 Year: 2022
Sputum induction for assessment of biomarkers in early development of new drugs for respiratory disease in a proof of concept setting Source: International Congress 2016 – Airway biomarkers Year: 2016
Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014
Applying new respiratory function technologies to the elderly and the potential of future lung regeneration Source: Virtual Congress 2020 – Lung health and respiratory function at all ages Year: 2020
Development of a new calcilytic for the treatment of inflammatory lung disease Source: International Congress 2018 – Basic pharmacology Year: 2018
Antibody and host inflammatory biomarker combinations as diagnostic tools for TB disease Source: International Congress 2017 – Update on TB: latest news Year: 2017
COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020 Year: 2020
Genetic studies as a tool for identifying novel potential targets for treatment of COPD Source: Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017 Year: 2017
Human small airway-on-a-chip: A novel microphysiological system to model lung inflammation, accelerate drug development and enable inhalational toxico-analysis Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016
A combinational approach to optimize biomarkers efficacy in identifying patients with sarcoidosis and monitoring respiratory functional worsening Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV Year: 2012
Circulating fibrocytes as a new tool to predict lung cancer progression after surgery? Source: Eur Respir J, 58 (6) 2101221; 10.1183/13993003.01221-2021 Year: 2021
COPD – will new insights into molecular pathology define new therapies? Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014